BSC
BMRN icon

BOLTON SECURITIES CORPORATION’s BioMarin Pharmaceuticals BMRN Stock Holding History

BOLTON SECURITIES CORPORATION’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-1,000
Closed -$57.2K – 2255
2026
Q2 		$57.2K Hold
1,000
– – ﹤0.01% 1284
2026
Q1 		$56.5K Buy
+1,000
New +$58.3K ﹤0.01% 1200
2025
Q3 		$162K Buy
+3,000
New +$172K 0.01% 799

Other funds holding BMRN

State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 38.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

BOLTON SECURITIES CORPORATION's BMRN Position: Q3 2026 in Review

BOLTON SECURITIES CORPORATION sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2026, closing a stake of 1,000 shares — an estimated $57.2K sold.

BOLTON SECURITIES CORPORATION first reported a position in BMRN in Q3 2025 and held it in 3 quarters. The position peaked at $162K in Q3 2025. 348 funds tracked by Wall St. Rank hold BMRN as of Q3 2026.

  • BOLTON SECURITIES CORPORATION reported no remaining BioMarin Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • BOLTON SECURITIES CORPORATION sold 1,000 BioMarin Pharmaceuticals shares in Q3 2026, an estimated $57.2K.
  • BOLTON SECURITIES CORPORATION first reported a position in BioMarin Pharmaceuticals in Q3 2025 and held it in 3 quarters.
  • BOLTON SECURITIES CORPORATION's BioMarin Pharmaceuticals position peaked at $162K in Q3 2025.
  • 348 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2026.

Based on BOLTON SECURITIES CORPORATION's 13F filing for Q3 2026, filed 12 Nov 2026.